These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 25834025)

  • 1. Attacks on publicly funded trials: what happens when industry does not want to know the answer.
    Cohen D
    BMJ; 2015 Apr; 350():h1701. PubMed ID: 25834025
    [No Abstract]   [Full Text] [Related]  

  • 2. Avastin is as effective as Lucentis in treating wet age related macular degeneration, study finds.
    Torjesen I
    BMJ; 2013 Jul; 347():f4678. PubMed ID: 23881948
    [No Abstract]   [Full Text] [Related]  

  • 3. Why have UK doctors been deterred from prescribing Avastin?
    Cohen D
    BMJ; 2015 Apr; 350():h1654. PubMed ID: 25834024
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost comparison of ranibizumab and bevacizumab.
    Jackson TL; Kirkpatrick L
    BMJ; 2011 Aug; 343():d5058. PubMed ID: 21862536
    [No Abstract]   [Full Text] [Related]  

  • 5. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 6. Legal. PCTs taken to court over use of cheaper drug.
    Calkin S
    Health Serv J; 2012 Apr; 122(6303):10-1. PubMed ID: 22741353
    [No Abstract]   [Full Text] [Related]  

  • 7. Provider, patient and public benefits from a NICE appraisal of bevacizumab (Avastin).
    Rhodes C; Harris J; Sulston J; Spanswick C
    J Med Ethics; 2012 Mar; 38(3):187-9. PubMed ID: 21947806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary care trusts reverse advice to ophthalmologists to use cheaper drug for wet age related macular degeneration.
    Hawkes N
    BMJ; 2012 Jul; 345():e5161. PubMed ID: 22846417
    [No Abstract]   [Full Text] [Related]  

  • 9. Novartis takes legal action over trusts' advice to use bevacizumab for wet AMD.
    Torjesen I
    BMJ; 2012 Apr; 344():e2959. PubMed ID: 22532011
    [No Abstract]   [Full Text] [Related]  

  • 10. A licence to cure.
    Aronson JK; Ferner RE
    BMJ; 2015 Apr; 350():h1723. PubMed ID: 25834026
    [No Abstract]   [Full Text] [Related]  

  • 11. CCGs face legal threat for offering off-label drug for wet AMD.
    Cohen D
    BMJ; 2017 Oct; 359():j5021. PubMed ID: 29089307
    [No Abstract]   [Full Text] [Related]  

  • 12. Why using Avastin for eye disease is so difficult.
    Torjesen I
    BMJ; 2012 May; 344():e3012. PubMed ID: 22549057
    [No Abstract]   [Full Text] [Related]  

  • 13. Age-related macular degeneration: treatment at what cost?
    The Lancet
    Lancet; 2018 Sep; 392(10153):1090. PubMed ID: 30303068
    [No Abstract]   [Full Text] [Related]  

  • 14. Avastin is as effective as Lucentis for wet AMD and could save NHS 84m pound a year, study shows.
    Hawkes N
    BMJ; 2012 May; 344():e3275. PubMed ID: 22573655
    [No Abstract]   [Full Text] [Related]  

  • 15. Implications of "not me" drugs for health systems: lessons from age related macular degeneration.
    Campbell RJ; Dhalla IA; Gill SS; Bell CM
    BMJ; 2012 May; 344():e2941. PubMed ID: 22549055
    [No Abstract]   [Full Text] [Related]  

  • 16. Avastin and Lucentis: a guide through the legal maze.
    Lock D
    BMJ; 2015 Apr; 350():h1377. PubMed ID: 25834023
    [No Abstract]   [Full Text] [Related]  

  • 17. Drugs for macular degeneration, price discrimination, and Medicare’s responsibility not to overpay.
    Silver J
    JAMA; 2014 Jul; 312(1):23-4. PubMed ID: 24860863
    [No Abstract]   [Full Text] [Related]  

  • 18. A clearer view of evidence in treating macular degeneration: off-label policies and independent research.
    Formoso G; Marata AM; Magrini N; Bero L
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):ED000090. PubMed ID: 25228121
    [No Abstract]   [Full Text] [Related]  

  • 19. Identifying and eliminating the roadblocks to comparative-effectiveness research.
    Martin DF; Maguire MG; Fine SL
    N Engl J Med; 2010 Jul; 363(2):105-7. PubMed ID: 20519677
    [No Abstract]   [Full Text] [Related]  

  • 20. US government is funding fewer trials as number of industry sponsored trials grows.
    Dyer O
    BMJ; 2015 Dec; 351():h6893. PubMed ID: 26684014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.